CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Completed · Phase 2

Conditions studied: B-cell Chronic Lymphocytic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Malignant Neoplasm, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia

In brief

Drugs used in chemotherapy, such as CCI-779, work in different ways to stop cancer cells from dividing so they stop growing or die. This phase II trial is studying how well CCI-779 works in treating patients with recurrent or refractory B-cell non-Hodgkin's lymphoma or chronic lymphocytic leukemia.

Key facts

Study ID: NCT00290472
Run by: National Cancer Institute (NCI)
People needed: 89
Starts: 2004-03-01
Expected to finish: 2010-04-01
Last updated by the study team: 2014-05-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Histologically or cytologically confirmed B-cell non-Hodgkin's lymphoma, including the following subtypes:
Aggressive B-cell lymphoma (Group A)
Diffuse large B-cell lymphoma
Transformed lymphoma
Follicular lymphoma (Group B)
Small lymphocytic lymphoma
Chronic lymphocytic leukemia (CLL) (Group C)
Other B-cell small lymphocytic disorders
No mantle cell lymphoma
No potentially curative treatment options because of lack of response, relapse, or ineligibility
Relapsed or refractory disease
Patients with refractory disease (i.e., less than a partial response to the last treatment) must have received no more than 3 prior regimens (group A)
Patients with sensitive disease (i.e., at least a partial response to the last treatment) must have received no more than 4 prior regimens (group A)
Patients who have failed prior autologous transplantation are eligible (group A)
No more than 5 prior regimens (groups B and C)
The salvage regimen, conditioning regimen, and any maintenance therapy are considered 1 regimen
Prior rituximab or alemtuzumab is not considered prior therapy
No limitation to the amount of prior radiotherapy
No CNS involvement
Performance status: ECOG 0-2 OR Karnofsky 60-100%
Life expectancy more than 3 months
No symptomatic congestive heart failure
No unstable angina pectoris
No cardiac arrhythmia
No prior allergic reactions attributed to compounds of similar chemical or biological composition to CCI-779

Where it is running

University of Chicago — Chicago, Illinois, United States
Decatur Memorial Hospital — Decatur, Illinois, United States
Evanston Hospital CCOP — Evanston, Illinois, United States
Ingalls Memorial Hospital — Harvey, Illinois, United States
Adventist La Grange Memorial Hospital — La Grange, Illinois, United States
Loyola University Medical Center — Maywood, Illinois, United States
Central Illinois Hematology Oncology Center — Springfield, Illinois, United States
Fort Wayne Medical Oncology and Hematology Inc-Parkview — Fort Wayne, Indiana, United States
Northern Indiana Cancer Research Consortium — South Bend, Indiana, United States
University of Iowa — Iowa City, Iowa, United States
Oncology Care Associates PLLC — Saint Joseph, Michigan, United States
M D Anderson Cancer Center — Houston, Texas, United States
Froedtert and the Medical College of Wisconsin — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.